HONG-KONG-SCIENCE
24.3.2023 03:01:29 CET | Business Wire | Press release
Hong Kong is open to all and Hong Kong Science and Technology Parks Corporation (HKSTP) is ramping up its seventh Elevator Pitch Competition (EPiC 2023) by unveiling its 50 Grand Finale semi-finalists, selected from 618 entries and 55 economies across the world.
EPiC 2023 -- backed by innovation-driven partners Cathay, HSBC, MTR Lab, plus world-leading accelerator Plug & Play -- is the city’s most eagerly anticipated pitch event each year and will take place on 28 April 2023 (Friday) at the summit of Hong Kong’s tallest building, the International Commerce Centre. The annual event is a unique, worldwide competition for mid to late-stage startups in the FinTech and PropTech sectors who seek to expand their footprints into Asia and beyond, while leveraging Hong Kong’s biggest innovation ecosystem at HKSTP.
EPiC provides the best available platform for startups to make real business impact through connections with the Science Park network of 1,000+ investors and 300+ corporate partners.
This year, three quarters of the entries are from overseas, with the proportion of overseas contestants and the number of economies participating hitting a record high since 2016. A total of 50 contestants representing 14 different economies entered the semi-final round.
All 50 semi-finalists have a golden opportunity to be considered for direct investment of up to US$5 million from the HKSTP Venture Fund, as well as market expansion support across Asia and beyond, plus the chance to win a cash prize of US$90,000 if crowned overall champion.
Albert Wong, CEO, HKSTP, said: “EPiC is an iconic mega event that has hit global scale, as record turnout from international startups further demonstrates Hong Kong’s advantages as an international I&T hub. Hong Kong is diversified, vibrant and attracts the very best entrepreneurs, investors and corporate innovators. Grow fast and go beyond is the theme for EPiC this year, and we welcome talents from around the world to explore Hong Kong’s unlimited investment and innovation opportunities.”
The EPiC Grand Finale on 28 April will be hosted at Hong Kong’s iconic Sky 100 venue atop Hong Kong’s tallest building, the International Commerce Centre. The 50 competing teams will pitch their world-changing ideas to a judging panel of renowned investors, entrepreneurs, and business leaders. The actual pitch will comprise of a 60-second elevator ride as participants compete for the title of overall EPiC Champion.
To propel EPiC to the broader public, HKSTP has launched for the first time, the "My Favourite Pitcher" public poll, which is open to all to vote for their favourite pitch video from the shortlisted 50 semi-finalists. The poll is now available at EPiC polling website (epic-voting.hkstp.org) and lasts until 28 April 2023 1pm (HKT). The semi-finalist with the highest number of votes will win the cash prize of US$10,000, plus 200,000 Asia Miles sponsored by Cathay.
HKSTP will also kick off the exclusive Immersion Programme for semi-finalists to experience Hong Kong’s I&T ecosystem first-hand and unlock business opportunities through educational talks, business matching and networking with leading corporate partners and investors across the HKSTP ecosystem.
Contestants Breakdown:
Category |
No. of applicants |
PropTech |
266 (43%) |
FinTech |
352 (57%) |
Headquarter |
No. of applicants |
Overseas |
465 (75%) |
Hong Kong |
153 (25%) |
A record high proportion of overseas contestants and economies participation since 2016.
EPiC activities:
Now until 28 April 2023, 1pm (HKT)
"My Favourite Pitcher" Public Polling
- The top 50 semi-finalists' pitching videos is open for public online voting
- The semi-finalist with the highest number of votes will be crowned EPiC 2023's "My Favourite Pitcher" and win the cash prize of US$10,000 plus 200,000 Asia Miles sponsored by Cathay
25 – 26 April 2023
"Grow Beyond Hong Kong" Immersion Programme
- An exclusive 2-day programme for EPiC 2023 semi-finalists to experience HKSTP’s innovation ecosystem.
- Participants will unlock growth opportunities through educational talks, business matching and networking with leading corporate partners and investors in our ecosystem.
28 April 2023
EPiC 2023 Grand Finale
- Venue: Sky100 Hong Kong Observation Deck
- Top 50 Semi-Finalists will pitch their ideas within a 60-second elevator ride
- Top 10 Finalists will pitch their innovation ideas on stage to renowned investors, entrepreneurs, and business leaders
- All 50 semi-finalists have the golden opportunities to be considered for direct investment of up to US$5 million from the HKSTP Venture Fund, plus the chance to win a cash prize of US$90,000 if crowned overall champion.
For more information on EPiC 2023, please visit: https://epic.hkstp.org/
For full list of the 50 semi-finalists see appendix below.
About Hong Kong Science and Technology Parks Corporation
Hong Kong Science and Technology Parks Corporation (HKSTP) has for over 20 years committed to building up Hong Kong as an international innovation and technology hub to propel success for local and global pioneers today and tomorrow. HKSTP has established a thriving I&T ecosystem that is home to two unicorns and Hong Kong’s leading R&D hub with over 12,000 research professionals and over 1,200 technology companies focused on healthtech, AI and robotics, fintech and smart city technologies.
Established in 2001, we attract and nurture talent, accelerate and commercialise innovation and technology for entrepreneurs on their journey of growth in Hong Kong, to the Greater Bay Area, Asia and beyond. Our growing innovation ecosystem is built around our key locations of Hong Kong Science Park in Shatin, InnoCentre in Kowloon Tong and three modern INNOPARKs in Tai Po, Tseung Kwan O and Yuen Long. The three INNOPARKs are realising a vision of new industrialisation for Hong Kong. The goal is sectors like advanced manufacturing, electronics and biotechnology are being reimagined for a new generation of industry.
Through our infrastructure, services, expertise and network of partnerships, HKSTP will help establish innovation and technology as a pillar of growth for Hong Kong, while reinforcing Hong Kong’s international I&T hub status as a launchpad for global growth at the heart of the GBA innovation powerhouse.
More information about HKSTP is available at www.hkstp.org.
APPENDIX:
50 semi-finalists for the Grand Finale of EPiC 2023, with 26 from FinTech and 24 from PropTech:
FinTech
Company Name (in alphabetical order) |
Headquarter |
|
1 |
AlgoBot Limited |
Hong Kong SAR China |
2 |
Amuro Limited |
Hong Kong SAR China |
3 |
Canvasland Limited |
Hong Kong SAR China |
4 |
Deland Labs |
Singapore |
5 |
Doconomy |
Sweden |
6 |
Dowsure |
Mainland China |
7 |
Endangered Wildlife OÜ |
Estonia |
8 |
FedML, Inc. |
United States |
9 |
FinCrime Dynamics |
United Kingdom |
10 |
Finema |
Thailand |
11 |
FINGREEN AI |
France |
12 |
PFY Healthcare Technology |
Mainland China |
13 |
Homebase |
Vietnam |
14 |
Leapstack |
Vietnam |
15 |
Miotech |
Mainland China |
16 |
Prometheus Technologies |
United States |
17 |
Redkik |
United States |
18 |
Revix |
United Kingdom |
19 |
Sensor data |
Mainland China |
20 |
Health Exchange Technology Service Group |
Mainland China |
21 |
Speedlegal |
United States |
22 |
Taos Technology LLC |
United States |
23 |
Ultipa |
Mainland China |
24 |
VoiceAI Technologies |
Mainland China |
25 |
Vymo |
United States |
26 |
Wequity |
Belgium |
PropTech
Company Name (in alphabetical order) |
Headquarter |
|
1 |
Archifiction |
Mainland China |
2 |
Bridge5 Asia |
Singapore |
3 |
Collov, Inc |
United States |
4 |
Dfocus |
Mainland China |
5 |
Doratoon |
Singapore |
6 |
EGG Lighting |
United Kingdom |
7 |
Firefly Dimension, Inc. |
United States |
8 |
FLX Solutions |
United States |
9 |
I2Cool Limited |
Hong Kong SAR China |
10 |
IronYun |
United States |
11 |
Kodifly Limited |
Hong Kong SAR China |
12 |
Layer Construction, Inc. |
United States |
13 |
Llewellyn and Partners Company Limited |
Hong Kong SAR China |
14 |
Mimicrete |
United Kingdom |
15 |
PassiveLogic |
United States |
16 |
Photinique Limited |
Hong Kong SAR China |
17 |
Rootie |
Israel |
18 |
SKYLAND INNOVATION COMPANY LIMITED |
Hong Kong SAR China |
19 |
Structure Pal |
Israel |
20 |
Swiss AI |
Switzerland |
21 |
Tensorflight, Inc. |
United States |
22 |
Umi Coating New Material Technology Co., Limited |
Hong Kong SAR China |
23 |
Visionaries 777 |
Hong Kong SAR China |
24 |
VoltSafe Inc. |
Canada |
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230324005001/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
